From Bench to Bedside: Immunotherapy for Prostate Cancer

被引:16
|
作者
Tse, Brian Wan-Chi [1 ]
Jovanovic, Lidija [1 ]
Nelson, Colleen Coyne [1 ]
de Souza, Paul [2 ]
Power, Carl Andrew [3 ]
Russell, Pamela Joan [1 ]
机构
[1] Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Translat Res Inst, Inst Hlth & Biomed Innovat, Brisbane, Qld 4102, Australia
[2] Univ Western Sydney, Sydney Sch Med, Ingham Inst Appl Med Res, Sydney, NSW 2170, Australia
[3] Univ New S Wales, Lowy Canc Res Ctr, Biol Resources Imaging Lab, Sydney, NSW 2052, Australia
关键词
ALLOGENEIC CELLULAR IMMUNOTHERAPY; REGULATORY T-CELLS; PHASE-I TRIAL; SIPULEUCEL-T; DOSE-ESCALATION; GM-CSF; ADAPTIVE IMMUNITY; CTLA-4; BLOCKADE; DOUBLE-BLIND; OPEN-LABEL;
D O I
10.1155/2014/981434
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The mainstay therapeutic strategy for metastatic castrate-resistant prostate cancer (CRPC) continues to be androgen deprivation therapy usually in combination with chemotherapy or androgen receptor targeting therapy in either sequence, or recently approved novel agents such as Radium 223. However, immunotherapy has also emerged as an option for the treatment of this disease following the approval of sipuleucel-T by the FDA in 2010. Immunotherapy is a rational approach for prostate cancer based on a body of evidence suggesting these cancers are inherently immunogenic and, most importantly, that immunological interventions can induce protective antitumour responses. Various forms of immunotherapy are currently being explored clinically, with the most common being cancer vaccines (dendritic-cell, viral, and whole tumour cell-based) and immune checkpoint inhibition. This review will discuss recent clinical developments of immune-based therapies for prostate cancer that have reached the phase III clinical trial stage. A perspective of how immunotherapy could be best employed within current treatment regimes to achieve most clinical benefits is also provided.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside
    Jieping Hu
    Qingke Chen
    International Urology and Nephrology, 2017, 49 : 369 - 380
  • [22] The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside
    Hu, Jieping
    Chen, Qingke
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2017, 49 (03) : 369 - 380
  • [23] Androgen receptor splice variants and prostate cancer: From bench to bedside
    Wadosky, Kristine M.
    Koochekpour, Shahriar
    ONCOTARGET, 2017, 8 (11) : 18550 - 18576
  • [24] THERAPY OF ENDOCRINE DISEASE Immunotherapy of advanced thyroid cancer: from bench to bedside
    Moretti, Sonia
    Menicali, Elisa
    Nucci, Nicole
    Guzzetti, Martina
    Morelli, Silvia
    Puxeddu, Efisio
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2020, 183 (02) : R41 - R55
  • [25] Cytokine induced killer cell immunotherapy in cancer treatment: from bench to bedside
    Arafar, Arashar
    BIOMEDICAL RESEARCH AND THERAPY, 2014, 1 (02): : 71 - 77
  • [26] CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside
    Zhu, Xingwang
    Xue, Jieyun
    Jiang, Hongzhou
    Xue, Dongwei
    MOLECULAR CANCER, 2024, 23 (01)
  • [27] Immunotherapy for invasive fungal infections: from bench to bedside
    Pappas, PG
    DRUG RESISTANCE UPDATES, 2004, 7 (01) : 3 - 10
  • [28] Immunotherapy for Recurrent Glioma-From Bench to Bedside
    Pu, Yi
    Zhou, Guanyu
    Zhao, Kejia
    Chen, Yaohui
    Shen, Shensi
    CANCERS, 2023, 15 (13)
  • [29] Natural killer cell immunotherapy: from bench to bedside
    Domogala, Anna
    Madrigal, J. Alejandro
    Saudemont', Aurore
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [30] Immunotherapy in Alzheimer's Disease: From the Bench to the Bedside
    Diniz, Breno S.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2024, 32 (05): : 584 - 585